克洛斯特里迪奥伊德困难感染与用Infliximab治疗的急性严重性结肠炎的结肠切除风险增加有关
Tamara F Kahan1, Olivia Delau1, Simon Hong1
1Division of Gastroenterology.
Journal of clinical gastroenterology
|November 7, 2025
概括
结肠切除术在急性严重性结肠炎 (ASUC) 中很常见,尽管使用了因弗力西马布 (IFX) 治疗. 困难菌感染和高CRP/白蛋白比率预测了在一年内切除瘤的风险,有助于早期干预策略.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 伊弗利西马布 (IFX) 是急性严重性结肠炎 (ASUC) 的关键治疗方法.
- 很大一部分ASUC患者 (高达30%) 仍然需要在IFX治疗一年内进行大肠切除.
- 有限的临床数据存在于ASUC患者接受IFX后集体切除术.
研究的目的:
- 在接受医院IFX的ASUC患者中识别胆管切除术的危险因素.
- 分析30天和1年内切除术的人口统计学,临床和实验室预测因素.
主要方法:
- 在2014-2022年期间接受IFX治疗的ASUC患者的回顾性分析.
- 利用考克斯的比例危险模型来评估风险因素.
- 在IFX启动后的30天和1年内评估的胆管切除率.
主要成果:
- 21.2%的患者 (36/170) 在1年内进行了小肠切除术;12.9% (22/170) 在30天内.
- 住院期间的Clostridioides difficile感染,降低的C-反应蛋白 (CRP) 反应,以及频繁的肠道排便预测了1年的胆管切除术在不变的分析中.
- 多变量分析确定了C. difficile感染 (aHR=2.92) 和更高的入院CRP/白蛋白比率 (aHR=1.13) 作为1年大肠切除术的显著预测因素.
结论:
- 在IFX治疗的ASUC患者中,克洛斯特里迪奥伊德困难感染和入院时CRP/白蛋白比率升高与在一年内切除术风险增加有关.
- 这些发现可以帮助分层患者进行及时干预,包括JAK抑制剂治疗或手术咨询.
- 早期识别高风险患者可以优化治疗途径,减少切除术延迟.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
880
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
880
Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
Inflammatory Bowel Disease V: Surgical Management
430
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
430
Inflammatory Bowel Disease II: Crohn's Disease
939
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
939
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
420
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
420


